Abstract
Patients with solid cancer frequently develop bone metastases (BM). Zoledronic acid (Zometa® Meldola, ZA), routinely used to treat patients with BM, acts on osteoclasts and also has antitumor properties. We aimed to assess the effect of ZA over time in novel bone turnover markers (RANK/receptor activator of nuclear factor-k B ligand (RANK-L)/ Osteoprotegerin (OPG)) and to correlate these with serum N-terminal telopeptide (NTX). The study prospectively evaluated levels of RANK, RANK-L and OPG transcripts by real-time PCR and NTX expression by ELISA in the peripheral blood of 49 consecutive patients with advanced breast, lung or prostate cancer. All patients received the standard ZA schedule and were monitored for 12 months. Median baseline values of RANK, RANK-L and OPG were 78.28 (range 7.34-620.64), 319.06 (21.42-1884.41) and 1.52 (0.10-58.02), respectively. At 12 months, the median RANK-L value had decreased by 22% with respect to the baseline, whereas median OPG levels had increased by about 96%. Consequently, the RANK-L/OPG ratio decreased by 56% from the baseline. Median serum NTX levels decreased over the 12-month period, reaching statistical significance (p <0.0001). Our results would seem to indicate that ZA modulates RANK, RANK-L and OPG expression, thus decreasing osteoclast activity.
| Original language | English |
|---|---|
| Pages (from-to) | 10683-10693 |
| Number of pages | 11 |
| Journal | International Journal of Molecular Sciences |
| Volume | 14 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - 2013 |
Fingerprint
Keywords
- Bone metastases
- NTX
- OPG
- RANK
- RANK-L
ASJC Scopus subject areas
- Physical and Theoretical Chemistry
- Organic Chemistry
- Spectroscopy
- Inorganic Chemistry
- Catalysis
- Molecular Biology
- Computer Science Applications
- Medicine(all)
Cite this
RANK/RANK-L/OPG in patients with bone metastases treated with anticancer agents and zoledronic acid : A prospective study. / Mercatali, Laura; Ricci, Marianna; Scarpi, Emanuela; Serra, Patrizia; Fabbri, Francesca; Ricci, Rossana; Liverani, Chiara; Zanoni, Michele; Zoli, Wainer; Maltoni, Roberta; Gunelli, Erica; Amadori, Dino; Ibrahim, Toni.
In: International Journal of Molecular Sciences, Vol. 14, No. 6, 2013, p. 10683-10693.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - RANK/RANK-L/OPG in patients with bone metastases treated with anticancer agents and zoledronic acid
T2 - A prospective study
AU - Mercatali, Laura
AU - Ricci, Marianna
AU - Scarpi, Emanuela
AU - Serra, Patrizia
AU - Fabbri, Francesca
AU - Ricci, Rossana
AU - Liverani, Chiara
AU - Zanoni, Michele
AU - Zoli, Wainer
AU - Maltoni, Roberta
AU - Gunelli, Erica
AU - Amadori, Dino
AU - Ibrahim, Toni
PY - 2013
Y1 - 2013
N2 - Patients with solid cancer frequently develop bone metastases (BM). Zoledronic acid (Zometa® Meldola, ZA), routinely used to treat patients with BM, acts on osteoclasts and also has antitumor properties. We aimed to assess the effect of ZA over time in novel bone turnover markers (RANK/receptor activator of nuclear factor-k B ligand (RANK-L)/ Osteoprotegerin (OPG)) and to correlate these with serum N-terminal telopeptide (NTX). The study prospectively evaluated levels of RANK, RANK-L and OPG transcripts by real-time PCR and NTX expression by ELISA in the peripheral blood of 49 consecutive patients with advanced breast, lung or prostate cancer. All patients received the standard ZA schedule and were monitored for 12 months. Median baseline values of RANK, RANK-L and OPG were 78.28 (range 7.34-620.64), 319.06 (21.42-1884.41) and 1.52 (0.10-58.02), respectively. At 12 months, the median RANK-L value had decreased by 22% with respect to the baseline, whereas median OPG levels had increased by about 96%. Consequently, the RANK-L/OPG ratio decreased by 56% from the baseline. Median serum NTX levels decreased over the 12-month period, reaching statistical significance (p <0.0001). Our results would seem to indicate that ZA modulates RANK, RANK-L and OPG expression, thus decreasing osteoclast activity.
AB - Patients with solid cancer frequently develop bone metastases (BM). Zoledronic acid (Zometa® Meldola, ZA), routinely used to treat patients with BM, acts on osteoclasts and also has antitumor properties. We aimed to assess the effect of ZA over time in novel bone turnover markers (RANK/receptor activator of nuclear factor-k B ligand (RANK-L)/ Osteoprotegerin (OPG)) and to correlate these with serum N-terminal telopeptide (NTX). The study prospectively evaluated levels of RANK, RANK-L and OPG transcripts by real-time PCR and NTX expression by ELISA in the peripheral blood of 49 consecutive patients with advanced breast, lung or prostate cancer. All patients received the standard ZA schedule and were monitored for 12 months. Median baseline values of RANK, RANK-L and OPG were 78.28 (range 7.34-620.64), 319.06 (21.42-1884.41) and 1.52 (0.10-58.02), respectively. At 12 months, the median RANK-L value had decreased by 22% with respect to the baseline, whereas median OPG levels had increased by about 96%. Consequently, the RANK-L/OPG ratio decreased by 56% from the baseline. Median serum NTX levels decreased over the 12-month period, reaching statistical significance (p <0.0001). Our results would seem to indicate that ZA modulates RANK, RANK-L and OPG expression, thus decreasing osteoclast activity.
KW - Bone metastases
KW - NTX
KW - OPG
KW - RANK
KW - RANK-L
UR - http://www.scopus.com/inward/record.url?scp=84878169309&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84878169309&partnerID=8YFLogxK
U2 - 10.3390/ijms140610683
DO - 10.3390/ijms140610683
M3 - Article
C2 - 23702841
AN - SCOPUS:84878169309
VL - 14
SP - 10683
EP - 10693
JO - International Journal of Molecular Sciences
JF - International Journal of Molecular Sciences
SN - 1661-6596
IS - 6
ER -